AMETEK, Inc. (AME): BCG Matrix [June-2026 Updated]

This ready-made BCG Matrix Analysis of AMETEK, Inc. Business gives you a clear, research-based view of where the portfolio is growing, where it throws off cash, and where capital may be best deployed. You'll see why Electronic Instruments Group looks like the main growth engine with about $5.00B of 2025 sales and Q1 2026 sales up 11.0%, why Electromechanical Group acts as a cash cow with about $2.40B of 2025 sales and a 22.7% Q4 margin, and how recent acquisitions such as FARO, Kern Microtechnik, LKC Technologies, First Aviation Services, and the $5.0B Indicor deal fit into the company's capital-allocation strategy. It also helps you assess portfolio balance using real figures such as $7.40B of 2025 sales, $1.70B of free cash flow, 26.2% adjusted operating margin, and the absence of a clear dog segment as of June 2026.

AMETEK, Inc. - BCG Matrix Analysis: Stars

AMETEK's Star businesses are its fastest-growing, highest-quality platforms, especially the Electronic Instruments Group. These units combine strong market demand, high margins, and recurring revenue, which is exactly what you want in a Star category. The key point is that AMETEK is not chasing low-quality growth; it is buying and building businesses with durable pricing power and technical depth.

Electronic Instruments Group is the clearest Star. It generated about $5.00B of 2025 sales, or roughly 68% of total company revenue. In Q1 2026, EIG sales rose 11.0% year over year to $1.26B. Orders were even stronger, reaching $2.20B, up 23%, with organic orders up 22%. Backlog climbed to a record $3.87B at March 31, 2026. That matters because backlog gives you visibility into future sales and supports the case that this segment is still in a growth phase rather than a mature cash cow.

AMETEK's niche strategy makes the Star profile stronger. The company focuses on markets with high barriers to entry, differentiated technology, and recurring revenue from consumables, services, and aftermarket support. That mix protects margins and reduces the risk of commoditization. In 2025, adjusted operating income reached $1.94B, and the adjusted operating margin was 26.2%. Full-year 2025 sales were $7.40B, up 6.6%, while adjusted diluted EPS rose 9% to $7.43. High margins plus growth is the classic Star combination because it shows the business can expand without giving up profitability.

The company is still funding growth, which is important for a Star. AMETEK spent $85M on incremental innovation and market-expansion efforts in 2025, and 2026 capital expenditures are guided at about $160M. This is not a maintenance-only spending pattern. It suggests management is still building technical capabilities, production capacity, and market reach. For academic analysis, this is a useful sign that the company is trying to extend the life of its growth franchises rather than squeeze short-term earnings.

Defense and automation are also supporting Star-like growth. AMETEK cited sustained demand in defense aftermarket, aerospace platforms, and advanced industrial automation as a 2026 tailwind. Q1 2026 net income was $399.4M, and adjusted diluted EPS was $1.97, up 13% from $1.75 a year earlier. The company also reported only about 2% of total sales from the Middle East, which lowers concentration risk. That matters because a Star should grow in resilient end markets, not depend on one volatile region or customer group.

• Defense aftermarket supports recurring service demand.
• Aerospace platforms create long product lifecycles and follow-on revenue.
• Industrial automation benefits from long-term productivity investment.
• Low Middle East exposure reduces geographic concentration risk.

AI and R&D strengthen the Star case further. AMETEK's June 2026 strategy explicitly names AI integration as a primary driver of long-term growth and competitive positioning. R&D is being directed toward mission-critical applications in medical, aerospace, defense, and automation. The company's 2025 sustainability and innovation disclosures show a willingness to fund transformation rather than simply manage mature assets. That matters in the BCG Matrix because Stars need reinvestment to defend market share while markets are still expanding.

AMETEK's balance sheet and market support also reinforce the Star profile. Its market capitalization was about $55.30B, institutional ownership stood near 87.43%, and capital deployment capacity was above $5.0B. High institutional ownership often reflects confidence in earnings durability, while strong capital capacity gives management room to keep buying growth. For students writing about BCG analysis, this is a good example of how financial strength supports strategic execution in a Star category.

Acquisitions are a major part of AMETEK's Star-building strategy. The company completed FARO Technologies in July 2025 for $920.0M and Kern Microtechnik in January 2025 for $51.6M. It also announced LKC Technologies in February 2026 and First Aviation Services in May 2026, while agreeing in May 2026 to buy Indicor's instrumentation portfolio for about $5.0B in cash. Indicor generated about $1.10B of 2025 sales and was valued at 14x EBITDA. That is a large, deliberate bet on higher-growth niches, not a harvesting move.

• FARO Technologies acquisition: $920.0M
• Kern Microtechnik acquisition: $51.6M
• First Aviation Services annual revenue: about $80M
• Indicor portfolio purchase price: about $5.0B
• Indicor 2025 sales: about $1.10B
• 2025 acquisition spending: $933.2M net of cash acquired

This acquisition cadence supports a Star classification because AMETEK is using capital to expand into technical, recurring, and high-barrier markets. In BCG terms, Stars need both market growth and strong relative market position. AMETEK's EIG segment, aerospace and defense exposure, innovation spending, and acquisition pace all point to businesses that can keep growing while holding or improving their competitive position.

AMETEK, Inc. - BCG Matrix Analysis: Cash Cows

AMETEK's Electromechanical Group fits the BCG Cash Cow category because it combines scale, strong margins, and recurring demand with relatively modest capital needs. This business generates reliable cash that can fund acquisitions, dividends, and balance-sheet discipline across the broader portfolio.

EMG Cash Yield is the clearest sign of Cash Cow strength. Electromechanical Group produced about $2.40B of 2025 sales, equal to roughly 32% of company revenue. Q4 2025 EMG sales rose 15% year over year to $628.9M, while operating margin expanded by 240 basis points to 22.7%. International sales made up 41% of EMG net sales, which shows a wide installed base and broad customer reach. A business with this kind of scale and margin usually sits in the mature, high-cash part of a BCG portfolio.

Free Cash Flow Machine is the second reason EMG belongs in Cash Cows. Full-year 2025 free cash flow was $1.70B, and net income conversion was 113%. That means AMETEK turned accounting profit into even more cash than reported earnings, which is a sign of strong working-capital control and efficient operations. For 2026, free cash flow conversion is expected to stay at 110% to 115% of net income. Full-year 2025 net income reached $1.48B, up 7.56% year over year, and adjusted diluted EPS was $7.43. The company also raised full-year 2026 adjusted EPS guidance to $7.94 to $8.14, which supports the view that cash generation remains durable.

• 2025 free cash flow: $1.70B
• Net income conversion: 113%
• 2026 expected free cash flow conversion: 110% to 115%
• 2025 net income: $1.48B
• 2025 adjusted diluted EPS: $7.43
• 2026 adjusted EPS guidance: $7.94 to $8.14

Installed Base Services strengthen the Cash Cow profile because recurring revenue is easier to defend than one-time equipment sales. AMETEK's revenue base comes from consumables, services, and aftermarket support, which usually repeat across long customer relationships. The company operates more than 220 manufacturing sites worldwide and employs about 21,500 people, giving it the scale to service a large installed base efficiently. Operating working capital was 16.5% of sales in Q1 2026, improving by 30 basis points year over year. AMETEK also paid $425M of debt maturities in 2025 while still supporting investment-grade credit retention, which matters because it shows the cash engine is strong enough to reduce obligations and still invest.

Margin Discipline is central to why this business fits the Cash Cow slot. AMETEK's adjusted operating margin for 2025 was 26.2%, which is high for an industrial company of this size. GAAP operating income was $1.91B, and adjusted operating income was $1.94B, so the results were not heavily distorted by unusual items. Q1 2026 sales were $1.93B, up 11.3%, showing that the cash base can still grow without heavy capital intensity. 2026 capex is guided at about $160M, or roughly 2% of sales, which is modest and leaves more cash available for acquisitions, buybacks, and dividends.

Dividend Support is another Cash Cow feature. AMETEK raised its quarterly cash dividend by 10% to $0.34 per share in February 2026. That move was supported by 2025 adjusted diluted EPS of $7.43 and free cash flow of $1.70B. Institutional ownership was about 87.43%, while insiders held 0.66%, which reflects a widely held company with a stable cash profile. With a market capitalization of about $55.30B, investors are clearly pricing in dependable earnings and cash generation rather than speculative growth. In BCG terms, this is exactly the kind of mature business that can fund the rest of the portfolio.

• Quarterly dividend increase: 10%
• New quarterly dividend: $0.34 per share
• Institutional ownership: 87.43%
• Insider ownership: 0.66%
• Market capitalization: $55.30B

Why it matters for BCG analysis is straightforward. Cash Cows should generate more cash than they need for maintenance investment, and AMETEK's Electromechanical Group does that through high margins, recurring demand, global distribution, and low capex intensity. That cash supports growth initiatives elsewhere in the portfolio, especially acquisitions and shareholder returns, while reducing pressure on the balance sheet.

AMETEK, Inc. - BCG Matrix Analysis: Question Marks

AMETEK's Question Marks are the newest acquisitions and niche platforms that can grow into stronger positions, but they still lack enough scale, disclosed share data, or proven earnings contribution. They matter because they show where AMETEK is spending capital to build future growth, even if the payoff is not yet visible in reported results.

In BCG terms, a Question Mark sits in a high-growth area but holds a weak or unproven market position. That creates strategic tension: the business can become a Star if AMETEK gains share, or it can stay small and consume capital without delivering enough return. For academic analysis, this part of the portfolio is where you test execution risk, integration risk, and capital allocation discipline.

Indicor portfolio is the clearest Question Mark. AMETEK agreed on May 6, 2026 to buy a portfolio of instrumentation businesses for about $5.0B in cash. The target generated about $1.10B of 2025 sales and was priced at 14x EBITDA, which signals that AMETEK is paying for quality and expected synergy, not just current earnings. Closing is expected in H2 2026, so the deal is not yet visible in reported revenue, margin, or cash flow. Management also said capital deployment capacity still exceeds $5.0B, which shows that the company is willing to make a major bet. Until the integration works and market share improves, this is still a large Question Mark, not a proven core asset.

LKC Technologies is another Question Mark because it sits in a specialized medical niche with limited disclosure. AMETEK announced the acquisition on February 3, 2026, but it has not disclosed the purchase price or annual revenue. That makes it hard to measure market share, which is one of the key tests in the BCG Matrix. The product line in pediatric and adult ophthalmology may have strong technical value, but without scale data, you cannot yet call it a Star. AMETEK's 2025 innovation spend rose by $85.0M, and the vitality index reached 26%, so the company is clearly funding new product growth. That internal support matters because Question Marks need investment before they can earn a leading position.

• Strategic upside: if clinical adoption rises, the business can move from niche presence to stronger market position.
• Strategic risk: if revenue stays small, it may remain a capital consumer.
• Academic angle: this is a good example of how innovation spending supports future portfolio growth.

First Aviation Services is a Question Mark because the revenue base is still too small relative to AMETEK's scale. AMETEK completed the acquisition on May 26, 2026, and First Aviation has about $80.0M in annual revenue. Compared with AMETEK's $7.40B 2025 sales base, that is only about 1.1% of group revenue. The business operates in defense and aviation MRO, where demand can be attractive because aircraft need maintenance even when new plane production slows. But AMETEK has not disclosed the acquisition's contribution to earnings or margins, so the market still lacks proof of operating leverage. The small size keeps it in Question Mark territory, even if the end market is healthy.

FARO Technologies is an integration-driven Question Mark. AMETEK acquired it in July 2025 for $920.0M, bringing in 3D measurement and imaging solutions that fit the company's automation and technology themes. AMETEK reported strong Q1 2026 orders of $2.20B and a record backlog of $3.87B, which suggests the broader business has enough activity to support integration. Still, no standalone post-acquisition revenue or market share has been disclosed as of June 2026. That means the asset has strategic logic, but the evidence is not yet strong enough to classify it as a Star. It remains a Question Mark because the next stage depends on execution, not just purchase price.

Kern Microtechnik is small but strategically relevant. AMETEK acquired Kern in January 2025 for $51.6M, and the business provides high-precision machining solutions that fit AMETEK's focus on differentiated, mission-critical technology. The issue is scale. Kern is still modest relative to AMETEK's $7.40B revenue base and $55.30B market cap. AMETEK's 2025 acquisition spending totaled $933.2M, and 2026 capex is about $160M, so capital is being spread across multiple priorities. Without disclosed market share or growth data, Kern cannot be treated as a Cow or Star. It remains a Question Mark because the business may have strong technical value but has not yet shown enough scale.

• Capital allocation test: AMETEK is using cash to buy growth rather than waiting for organic expansion alone.
• Portfolio test: these deals are meaningful only if they improve revenue quality, margins, and cash generation.
• Execution test: integration speed will decide whether these assets become stronger positions or stay small bets.

AMETEK, Inc. - BCG Matrix Analysis: Dogs

AMETEK, Inc. does not show a clear, material dog segment in its public reporting as of June 2026. The company's latest results point to broad demand strength, high margins, and strong cash generation, which are not the signs of a low-growth, low-share business unit that drags on the portfolio.

In BCG Matrix terms, a dog is a business with weak market growth and weak relative market share. AMETEK's reported figures point in the opposite direction. 2025 sales rose 6.6% to $7.40B, Q1 2026 sales rose 11.3% to $1.93B, adjusted operating margin was 26.2%, and free cash flow conversion was 113%. Those are not the patterns you normally see in a business stuck in a dog quadrant.

The backlog and order data matter because they show the business is supported by current and near-term demand. Q1 2026 organic orders grew 22%, total orders rose 23%, and backlog reached a record $3.87B. Q1 2026 adjusted EPS increased to $1.97. A dog usually has shrinking demand, weak pricing power, and limited reinvestment appeal. AMETEK's reported numbers do not fit that pattern.

• Q1 2026 orders of $2.20B were above quarterly sales, which supports future revenue conversion.
• Organic orders growing 22% shows demand strength without relying only on acquisitions.
• Backlog of $3.87B gives the company a buffer against short-term softness.
• Adjusted EPS of $1.97 and adjusted operating margin of 26.2% indicate that current units are earning attractive returns.

AMETEK's strategy also works against dog formation. The company focuses on operational excellence, strategic acquisitions, global expansion, and technology innovation. It targets niche markets with high barriers to entry and recurring revenue from consumables, services, and aftermarket support. That model usually protects share and pricing, which makes it harder for weak units to linger in the portfolio.

The company invested $85.0M in innovation and market expansion during 2025 and plans about $160M of capex in 2026. That spending pattern points toward growth and productivity, not toward keeping unproductive assets alive. In BCG terms, the capital is being directed toward businesses with better growth and return potential, not toward low-value holdings.

• Operational excellence improves margins and lowers the chance that a business unit becomes a drag.
• Acquisitions shift capital into stronger niches rather than weak legacy assets.
• Recurring revenue from aftermarket service reduces cyclicality and supports retention.
• Capex focused on innovation and expansion helps preserve competitive position.

Capital recycling further reduces the chance of a meaningful dog. AMETEK spent $933.2M on acquisitions net of cash acquired in 2025 and announced more deals in 2026, including LKC, First Aviation, and the $5.0B Indicor instrumentation agreement. It also paid down $425M of debt maturities in 2025 while keeping investment-grade credit as a stated objective. This shows disciplined use of capital, with money moving toward higher-return assets and away from underperforming ones.

For valuation and strategy work, this matters because dogs can trap capital and depress returns on invested capital. AMETEK's market capitalization of about $55.30B and institutional ownership of 87.43% suggest investors expect disciplined portfolio management, not long-term support for weak assets. That does not prove every unit is strong, but it does show the company is not publicly presenting a large weak segment.

Market confidence also argues against a large dog presence. BlackRock held about 18.83M shares, or 8.21% of the company, while insiders held only 0.66%. AMETEK's 2026 adjusted EPS guidance of $7.94 to $8.14 implies 7% to 10% growth, and sales guidance remains in the high single digits. The 2025 dividend increase of 10% to $0.34 per share also fits a company with a strong cash base.

When you use BCG Matrix analysis in an academic paper, AMETEK is better discussed as a company with limited visible dog exposure rather than as a business with a clear dog category. The public data show growth, backlog support, strong margins, and active capital recycling, all of which reduce the case for a materially weak segment.